Some reports claim that gentamicin and amikacin levels may be raised by indometacin, and that amikacin levels may be raised by
ibuprofen lysine, when given to premature babies to treat patent ductus arteriosus, whereas others have not found an interaction.
Concurrent use should be closely monitored because of the
toxicity that is associated with raised aminoglycoside levels. It has been suggested that the aminoglycoside dosage should be reduced before giving indometacin. It has also been suggested that the dose interval of amikacin should be increased by at least 6 to 8 hours if
ibuprofen lysine is also given during the first days of life. The
serum levels of the
aminoglycosides and
renal function should be well monitored during concurrent use. Other
aminoglycosides possibly behave similarly. This interaction does not seem to have been studied in adults.